Neoplasms

Symptoms and General Pathology

All Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Neoplasm Metastasis

Breast Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Antineoplastic Agents

All Drugs and Chemicals

Capecitabine

Antimetabolites

Pharmacokinetic of its metabolites.

Capecitabine, 1250 mg/m2 twice a day

Nicole TUBIANA-MATHIEU, MD

The aim of the study is to determine blood concentration evolution of capecitabine and its active metabolites, in elderly patient 75 years and more.

Blood samples will be taken before 1rst course of chemotherapy of capécitabine for colorectal or breast metastatic cancer.

Pharmacokinetic will be realizes at several times (H0,5, H1, H1,5, H2, H4, H6, H8) and repeated at D14 of the 2d cycle

Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)

Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥75 Years)

University Hospital, Limoges

Neoplasms, Second Primary

Neoplastic Processes

Angiogenesis Inhibitors

Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.

CEUS (Contrast-enhanced ultrasound)

RECIST criteria for evaluating tumor response are often inadequate for the evaluation of anti-angiogenic drugs. An evaluation model of tumor perfusion with contrast-enhanced ultrasonography was developed at Gustave Roussy. It assesses the tumor vascular response through the analysis of 7 different parameters. Several studies (four at IGR, involving 117 patients, and a multicenter study involving 400 patients) showed that CEUS allows early evaluation of the effect of anti-angiogenic drugs. Two of these parameters are particularly interesting for the early identification of patients responding (or not) to treatment. Those are area under curve , and area under the wash-out. To further validate the use of these parameters, it is essential to measure and describe the level of their intra-patient variability.

Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast

Demonstrate that for the hepatic metastatic sites and for non hepatic metastatic sites the variability of the measured quantitative parameters on two different perfusion curves is less than 30%

Gustave Roussy, Cancer Campus, Grand Paris

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)	NCT00812864	Breast Cancer Colorectal Canc...	Capecitabine	75 Years -	University Hospital, Limoges
Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast	NCT02666690	GIST Metastatic... Breast Metastat... Kidney Metastat... Colon Metastati... Rectal Metastat...	CEUS (Contrast-...	18 Years - 80 Years	Gustave Roussy, Cancer Campus, Grand Paris
Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast	NCT02666690	GIST Metastatic... Breast Metastat... Kidney Metastat... Colon Metastati... Rectal Metastat...	CEUS (Contrast-...	18 Years - 80 Years	Gustave Roussy, Cancer Campus, Grand Paris

Spots Global Cancer Trial Database for breast metastatic cancer